ClinicalTrials.gg
CompletedNCT02794285TULIP SLE LTEUpdated Jan 13, 2023Results posted

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

A Phase 3 interventional study of Anifrolumab and Placebo in Active Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 175 sites in 24 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-01-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
559
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Connective Tissue Diseases with a site in United States — 17 open to participants now, 27 under way, 12 of them phase 3. Connective Tissue Diseases · United States.

Enrollment
10th of 68
559 · median 67
Started
2016
with 1 other
Phase 3
20 of 95
6 open now
Registered
55th of 95
by date

Among the 95 studies in Connective Tissue Diseases with a site in United States, this one is the 10th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2016, is one of 20 in phase 3, and was the 55th registered.

Connective Tissue Diseases

192 studies on the registry are indexed under Connective Tissue Diseases; 56 are open to participants now.

Browse Connective Tissue Diseases studies →

Open to participants now

17 of the 95 studies in Connective Tissue Diseases with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Connective Tissue Diseases studies recruiting now, 30 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Connective Tissue Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab.

Read the detailed description

This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled extension study to characterising the long term safety and tolerability of of an intravenous treatment regimen of anifrolumab versus placebo in subjects with moderately to severely active systemic lupus erythematosus who completed a Phase 3 study (D3461C00004 or D3461C00005) through the 52-week double-blind treatment period.

03

Conditions studied

  • Active Systemic Lupus Erythematosus

Keywords

  • Lupus Erythematosus, Systemic Autoimmune Diseases, Connective Tissue Diseases,Immune System Diseases
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have qualified for and received product (anifrolumab or placebo) and completed the treatment period in Studies D3461C00004 or D3461C00005 (through Week 52)
  2. Adequate peripheral venous access
  3. Females with an intact cervix should have documentation of a Pap smear with no documented within 90 days before Day 1/Visit 1 or 30 days following Day 1/Visit 1. Since access to a Pap smear may vary by country, the Sponsor recommends that local guidelines for obtaining Pap smears in subjects who have received immunomodulators or treatment be followed.
  4. Meets the following TB criteria:

    1. Negative QuantiFERON®-TB Gold [QFT-G] test result for TB obtained from the study central laboratory at Week 52 of Studies D3461C00004 or D3461C00005; OR
    2. Newly positive QFT-G test result at Week 52 of Studies D3461C00004 or D3461C00005 from the study central laboratory. A chest x-ray must be performed. If the chest x-ray shows no evidence of active TB, and the subject has no symptoms or medical history consistent with active TB, the subject must have a retest. If the retest is positive, the subject must start on prophylaxis within 30 days of randomisation but prior to the second dose of investigational product (Visit 2/Week 4); OR
    3. Positive but not newly positive QFT-G test at Week 52 of Studies D3461C00004 or D3461C00005. The subject must have been diagnosed with latent TB and must have documentation confirming initiation of appropriate treatment OR initiate treatment for latent TB within 30 days of randomization, but prior to the second dose of investigational product administration (Visit 2/Week 4)
    4. Newly indeterminate (confirmed on retest unless prior positive QFT G was documented, along with completed treatment for latent TB) or indeterminate but not newly indeterminate QFT-G test result at Week 52 of Studies D3461C00004 or D3461C00005 from the study central laboratory with ongoing QFT-G testing for TB according to the Study Plan
  5. In the opinion of the Investigator, subject must be able to comprehend the ICF and all protocol related assessments

Exclusion criteria

Exclusion Criteria:

  1. Receipt of any of the following within the last 60 days:

    1. Azathioprine >200 mg/day
    2. Mycophenolate mofetil >2.0 g/day /mycophenolic acid >1.44 g/day
    3. Oral, subcutaneous, or intramuscular methotrexate >25 mg/week
    4. Mizoribine >150 mg/day
  2. Receipt of any product (small molecule or biologic agent other than anifrolumab) within 4 weeks or 5 half-lives prior to Day 1/Visit 1, whichever is greater
  3. Receipt of any of the following:

    1. Any live or attenuated vaccine within 8 weeks prior to Day 1/Visit 1 (administration of killed vaccines is acceptable, the Sponsor recommends Investigators ensure all subjects are up to date on required vaccinations, including influenza [inactivated/recombinant] vaccine prior to study entry)
    2. Bacillus Calmette-Guerin (BCG) vaccine between the end of Studies D3461C00004 or D3461C00005 and Day 1/Visit 1
  4. Active severe SLE-driven renal or neuropsychiatric disease
  5. Any underlying condition that predisposes the subject to infection, including history of/current (HIV) infection
  6. Subjects with core antibody (HBcAb) positivity at enrolment of Studies D3461C00004 or D3461C00005 will be tested every 3 months for Hepatitis B virus (HBV) DNA. To remain eligible in the LTE study, subject HBV DNA levels must remain below the lower limit of quantitation as per the central laboratory.
  7. Opportunistic infection requiring hospitalisation or parenteral antimicrobial treatment within 3 years of Day 1/Visit 1
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
559 participants (actual)

Study arms

  • Experimental
    Anifrolumab

    Anifrolumab

    Biological: Anifrolumab

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • BiologicalAnifrolumab

    Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses

  • DrugPlacebo

    Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses

06

What researchers measure

Primary outcomes

  1. Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs)

    The event rate per 100 participant years was defined as the number of participants with an event divided by the sum of exposure time during the LTE study (including follow-up) in days for all participants in the analysis set multiplied by 365.25 days/year multiplied by 100. The exposure in a time period for each participant was calculated as end of period - start of period + 1. EAIRs of AESIs are presented as event rate per 100 participant years. The following AESIs were pre-defined: * Non-opportunistic serious infections * Opportunistic infections * Anaphylaxis * Malignancy * Herpes zoster * Tuberculosis (TB) (including latent TB) * Influenza * Vasculitis (non-systemic lupus erythematosus \[SLE\]) * Major cardiovascular events as according to the Cardiovascular Event Adjudication Committee.

    Time frame: Up to a maximum of 1114 days

  2. EAIRs of Serious Adverse Events (SAEs)

    EAIRs of SAEs are presented as event rate per 100 participant years. An SAE was an AE occurring during any study phase that fulfils 1 or more of the following criteria: * Results in death * Is immediately life-threatening * Requires in-patient hospitalisation or prolongation of existing hospitalisation * Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions * Is a congenital abnormality or birth defect * Is an important medical event that may jeopardise the participant or may require medical intervention to prevent one of the outcomes listed above.

    Time frame: Up to a maximum of 1114 days

07

Results

Posted Jan 13, 2023

Participant flow

This long-term extension (LTE) study was conducted at 176 study centres in 24 countries.

Participant flow — Overall Study
MilestoneRandomised Anifrolumab 300 mgPlacebo Feeder + Placebo LTEPlacebo Feeder + Anifrolumab 300 mg LTEAnifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE
Started25711211167
Completed178546941
Not completed79584226
Withdrew: Adverse event11458
Withdrew: Condition under investigation improved1000
Withdrew: Condition under investigation worsened0210
Withdrew: Death2120
Withdrew: Development of study-specific withdrawal criteria1001
Withdrew: Failure to meet randomisation criteria0010
Withdrew: Lack of efficacy10633
Withdrew: Lost to follow-up5631
Withdrew: Severe non-compliance to protocol1210
Withdrew: Withdrawal by subject38292012
Withdrew: Missing1000
Withdrew: Due to covid-19 pandemic7240
Withdrew: Other - not due to covid-19 pandemic2621

Outcome measures

PrimaryExposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs)

The event rate per 100 participant years was defined as the number of participants with an event divided by the sum of exposure time during the LTE study (including follow-up) in days for all participants in the analysis set multiplied by 365.25 days/year multiplied by 100. The exposure in a time period for each participant was calculated as end of period - start of period + 1. EAIRs of AESIs are presented as event rate per 100 participant years. The following AESIs were pre-defined: * Non-opportunistic serious infections * Opportunistic infections * Anaphylaxis * Malignancy * Herpes zoster * Tuberculosis (TB) (including latent TB) * Influenza * Vasculitis (non-systemic lupus erythematosus \[SLE\]) * Major cardiovascular events as according to the Cardiovascular Event Adjudication Committee.

Time frame:
Up to a maximum of 1114 days
Reported as:
Number · Events per 100 participant years
Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs)
Events per 100 participant yearsRandomised Anifrolumab 300 mgPlacebo Feeder + Placebo LTEPlacebo Feeder + Anifrolumab 300 mg LTEAnifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE
Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs)11.09.612.912.5
PrimaryEAIRs of Serious Adverse Events (SAEs)

EAIRs of SAEs are presented as event rate per 100 participant years. An SAE was an AE occurring during any study phase that fulfils 1 or more of the following criteria: * Results in death * Is immediately life-threatening * Requires in-patient hospitalisation or prolongation of existing hospitalisation * Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions * Is a congenital abnormality or birth defect * Is an important medical event that may jeopardise the participant or may require medical intervention to prevent one of the outcomes listed above.

Time frame:
Up to a maximum of 1114 days
Reported as:
Number · Events per 100 participant years
EAIRs of Serious Adverse Events (SAEs)
Events per 100 participant yearsRandomised Anifrolumab 300 mgPlacebo Feeder + Placebo LTEPlacebo Feeder + Anifrolumab 300 mg LTEAnifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE
EAIRs of Serious Adverse Events (SAEs)8.511.210.110.7

Adverse events

Collected over Day 1 up to until follow-up visit 2 (Week 164). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomised Anifrolumab 300 mg3/257 (1.2%)56/257 (21.8%)195/257 (75.9%)
Placebo Feeder + Placebo LTE1/112 (0.9%)27/112 (24.1%)79/112 (70.5%)
Placebo Feeder + Anifrolumab 300 mg LTE3/111 (2.7%)26/111 (23.4%)81/111 (73%)
Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE2/67 (3%)14/67 (20.9%)53/67 (79.1%)
Most frequent serious events
Showing 10 of 119
Most frequent serious events
EventRandomised Anifrolumab 300 mgPlacebo Feeder + Placebo LTEPlacebo Feeder + Anifrolumab 300 mg LTEAnifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders6/2576/1121/1112/67
PneumoniaInfections and infestations6/2572/1123/1113/67
COVID-19 pneumoniaInfections and infestations3/2011/643/820/42
Herpes zosterInfections and infestations6/2571/1123/1111/67
COVID-19Infections and infestations4/2010/642/820/42
GastroenteritisInfections and infestations1/2571/1122/1110/67
BronchitisInfections and infestations0/2570/1122/1110/67
Bacterial sepsisInfections and infestations0/2570/1120/1111/67
Cellulitis staphylococcalInfections and infestations0/2570/1120/1111/67
Pneumocystis jirovecii pneumoniaInfections and infestations0/2570/1120/1111/67
Most frequent other events
Showing 10 of 27
Most frequent other events
EventRandomised Anifrolumab 300 mgPlacebo Feeder + Placebo LTEPlacebo Feeder + Anifrolumab 300 mg LTEAnifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE
NasopharyngitisInfections and infestations63/25713/11229/11115/67
BronchitisInfections and infestations41/2579/11217/11116/67
Urinary tract infectionInfections and infestations57/25716/11218/1119/67
Upper respiratory tract infectionInfections and infestations55/25718/11222/1118/67
Herpes zosterInfections and infestations16/2576/11212/11110/67
HeadacheNervous system disorders28/25711/1127/11110/67
PharyngitisInfections and infestations20/2575/11212/1119/67
Back painMusculoskeletal and connective tissue disorders18/25710/11212/1119/67
GastroenteritisInfections and infestations7/2577/11213/1113/67
InsomniaPsychiatric disorders8/2573/1125/1117/67

Baseline characteristics

Full Analysis Set (FAS) - LTE Study: consisted of all participants who were randomised and received at least 1 dose of investigational product in the LTE Study.

Age, Categorical
Age, Categorical(Participants)Randomised Anifrolumab 300 mgPlacebo Feeder + Placebo LTEPlacebo Feeder + Anifrolumab 300 mg LTEAnifrolumab 150 mg Feeder + Anifrolumab 300 mg LTETotal
<=18 years00000
Between 18 and 65 years24711110765530
>=65 years1014217
Age, Continuous
Age, Continuous(Years)Randomised Anifrolumab 300 mgPlacebo Feeder + Placebo LTEPlacebo Feeder + Anifrolumab 300 mg LTEAnifrolumab 150 mg Feeder + Anifrolumab 300 mg LTETotal
Mean43.4 ± 11.5141.4 ± 11.4642.2 ± 12.2442.4 ± 11.7042.6 ± 11.67
Sex: Female, Male
Sex: Female, Male(Participants)Randomised Anifrolumab 300 mgPlacebo Feeder + Placebo LTEPlacebo Feeder + Anifrolumab 300 mg LTEAnifrolumab 150 mg Feeder + Anifrolumab 300 mg LTETotal
Female23710310263505
Male2099442
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Randomised Anifrolumab 300 mgPlacebo Feeder + Placebo LTEPlacebo Feeder + Anifrolumab 300 mg LTEAnifrolumab 150 mg Feeder + Anifrolumab 300 mg LTETotal
White173777045365
Black or African American2811171066
Asian331012661
Native Hawaiian or Other Pacific Islander00000
American Indian or Alaska Native31004
Other151110642
Missing52209
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Randomised Anifrolumab 300 mgPlacebo Feeder + Placebo LTEPlacebo Feeder + Anifrolumab 300 mg LTEAnifrolumab 150 mg Feeder + Anifrolumab 300 mg LTETotal
Hispanic or Latino54282214118
Not Hispanic or Latino198828753420
Missing52209
08

Study locations

175 sites
  • Research Site
    Birmingham, Alabama 35294-3280, United States
  • Research Site
    El Cajon, California 92020, United States
  • Research Site
    Hemet, California 92543, United States
  • Research Site
    La Jolla, California 92037, United States
  • Research Site
    Los Alamitos, California 90720, United States
  • Research Site
    Los Angeles, California 90024, United States
  • Research Site
    San Leandro, California 94578, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Upland, California 91786, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Bridgeport, Connecticut 06606, United States
  • Research Site
    Brandon, Florida 33511, United States
  • Research Site
    DeBary, Florida 32713, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Miami, Florida 33180, United States
  • Research Site
    Ormond Beach, Florida 32174, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    Vero Beach, Florida 32960, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Decatur, Georgia 30033, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Marietta, Georgia 30060, United States
  • Research Site
    Boise, Idaho 83702, United States
  • Research Site
    Idaho Falls, Idaho 83404, United States
  • Research Site
    Cumberland, Maryland 21502, United States
  • Research Site
    Hagerstown, Maryland 21740, United States
  • Research Site
    Grand Rapids, Michigan 49546, United States
  • Research Site
    Minneapolis, Minnesota 55455-0341, United States
  • Research Site
    Nashua, New Hampshire 03060, United States
  • Research Site
    Freehold, New Jersey 07728, United States
  • Research Site
    Las Cruces, New Mexico 88011, United States
  • Research Site
    Brooklyn, New York 11201, United States
  • Research Site
    Great Neck, New York 11021, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Charlotte, North Carolina 28210, United States
  • Research Site
    Charlotte, North Carolina 28277, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Raleigh, North Carolina 27617, United States
  • Research Site
    Middleburg Heights, Ohio 44130, United States
  • Research Site
    Oklahoma City, Oklahoma 73102, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Reading, Pennsylvania 19610, United States
  • Research Site
    North Charleston, South Carolina 29406, United States
  • Research Site
    Memphis, Tennessee 38104, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Amarillo, Texas 79124, United States
  • Research Site
    Austin, Texas 78726, United States
  • Research Site
    Austin, Texas 78745, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77034, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    Mesquite, Texas 75150, United States
  • Research Site
    Stafford, Texas 77477, United States
  • Research Site
    Spokane, Washington 99204, United States
  • Research Site
    Milwaukee, Wisconsin 53217, United States
  • Research Site
    Mendoza, 5500, Argentina
  • Research Site
    Quilmes, 1878, Argentina
  • Research Site
    San Miguel de Tucuman, T4000AXL, Argentina
  • Research Site
    Fitzroy, 3065, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Plovdiv, 4003, Bulgaria
  • Research Site
    Hamilton, Ontario L8S 4K1, Canada
  • Research Site
    Rimouski, Quebec G5L 5T1, Canada
  • Research Site
    Osorno, 5311092, Chile
  • Research Site
    Santiago, 8320000, Chile
  • Research Site
    Vina del Mar, 2520997, Chile
  • Research Site
    Armenia, 630004, Colombia
  • Research Site
    Barranquilla, 080002, Colombia
  • Research Site
    Medellín, 050021, Colombia
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Lille, 59037, France
  • Research Site
    Montpellier CEDEX 5, 34295, France
  • Research Site
    Paris Cedex 13, 75651, France
  • Research Site
    Paris cedex 14, 75014, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Frankfurt am Main, 60528, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Jena, 07747, Germany
  • Research Site
    Kirchheim, 73230, Germany
  • Research Site
    Mainz Am Rhein, 55131, Germany
  • Research Site
    Budapest, 1097, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Zalaegerszeg, 8900, Hungary
  • Research Site
    Haifa, 31048, Israel
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Kfar Saba, 49281, Israel
  • Research Site
    Tel Aviv, 64239, Israel
  • Research Site
    Chiba-shi, 260-8712, Japan
  • Research Site
    Chuo-ku, 104-8560, Japan

Showing the first 100 of 175 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang LJ, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al-Mossawi H. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi: 10.1002/art.42392. Epub 2022 Nov 11. PubMed 36369793 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Dec 2021, 65 months.

Results were first posted in Jan 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2016
First posted
Jun 9, 2016
StartActual
Jun 30, 2016
Primary completionActual
Dec 21, 2021
CompletionActual
Dec 21, 2021
Results first posted
Jan 13, 2023
Last update
Jan 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02794285
Lead sponsor
AstraZeneca
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Jun 9, 2016
Start date
Jun 30, 2016
Primary completion
Dec 21, 2021
Completion
Dec 21, 2021
Results posted
Jan 13, 2023
Last update
Jan 13, 2023

Study contacts

Kenneth Kalunian, MD
principal investigator · University of California, San Diego
Raj Tummala, MD
study director · AstraZeneca

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion